Sylvia McMahan
Family · Corpus Christi, TXNPI 1811481302
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,786 of the $6,747 with a category attached, or 85.8%. 25 manufacturers reported payments, led by Novo Nordisk at 26.1% of the total. Reporting peaked in 2022 at $2,500 and has fallen 59.8% since, to $1,006 in 2025. Among family clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 224 payments — averaging $30.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Nevro Corp.$2K
- Lilly USA, LLC$890
- AstraZeneca$537
- AbbVie$317
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$185
- plus $1K from 19 others
What the payments were for
- Travel & lodging$86413%
- Food & beverage$5,78686%
- Education$971%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 81 | $1,759 |
| Nevro Corp. | 16 | $1,743 |
| Lilly USA, LLC | 45 | $890 |
| AstraZeneca(2 entities) | 9 | $537 |
| AbbVie | 15 | $317 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $185 |
| Dexcom, Inc. | 3 | $184 |
| Biohaven Pharmaceuticals, Inc. | 5 | $184 |
| Amarin Pharma, Inc. | 6 | $127 |
| GSK | 4 | $111 |
| Amgen | 6 | $111 |
| Boehringer Ingelheim | 4 | $101 |
| Pfizer | 5 | $89 |
| Shield Therapeutics Inc | 5 | $74 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $57 |
| Exact Sciences | 2 | $53 |
| Bayer | 2 | $50 |
| Tris Pharma Inc | 1 | $29 |
| Almatica Pharma LLC | 1 | $25 |
| Pulmonx Corporation | 1 | $24 |
| Eisai Inc. | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Phadia US Inc. | 1 | $19 |
| Adlon Therapeutics L.p. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Senza$1,207
- FARXIGA$329
- Wegovy$239
- DEXCOM G7 GSS (161)$134
- DEXCOM STELO GLUCOSE BIOSENSOR$134
- CAPLYTA$126
- NURTEC ODT$125
- Ozempic$124
- KISUNLA$116
How this compares
$6,747 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 138 | $169,683 |
| FarxigaDapagliflozin Propanediol | 27 | $30,040 |
| Xigduo XrDapaglifloz Propaned/Metformin | 16 | $21,298 |
| MounjaroTirzepatide | 16 | $21,183 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $21,140 |
| EliquisApixaban | 18 | $18,118 |
| VascepaIcosapent Ethyl | 22 | $16,624 |
| JardianceEmpagliflozin | 14 | $11,556 |
| Icosapent Ethyl | 12 | $3,954 |
| Omega-3 Acid Ethyl Esters | 17 | $2,815 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $2,697 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 43 | $1,915 |
| Atorvastatin Calcium | 208 | $1,790 |
| Metoprolol Succinate | 105 | $1,307 |
| Gabapentin | 78 | $1,263 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,759 | $169,683138 claims |
| AstraZenecaFarxiga | $537 | $30,04027 claims |
| Lilly USA, LLCMounjaro | $890 | $21,18316 claims |
| GSKTrelegy Ellipta | $111 | $21,14022 claims |
| PfizerEliquis | $89 | $18,11818 claims |
| Boehringer IngelheimJardiance | $101 | $11,55614 claims |
| AbbVieSynthroid | $317 | $53114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in Corpus Christi
- Stephanie RodriguezCorpus Christi$159K
- Katie MontgomeryCorpus Christi$29K
- David WeirDallas$959K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
- Angela AchaPflugerville$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.